NO20051847L - Eikosapentaensyre (EPA) for behandling av anoreksia nevrosa (AN) og bulimi. - Google Patents

Eikosapentaensyre (EPA) for behandling av anoreksia nevrosa (AN) og bulimi.

Info

Publication number
NO20051847L
NO20051847L NO20051847A NO20051847A NO20051847L NO 20051847 L NO20051847 L NO 20051847L NO 20051847 A NO20051847 A NO 20051847A NO 20051847 A NO20051847 A NO 20051847A NO 20051847 L NO20051847 L NO 20051847L
Authority
NO
Norway
Prior art keywords
neurosis
bulimia
anorexia
epa
treatment
Prior art date
Application number
NO20051847A
Other languages
English (en)
Inventor
David Frederick Horrobin
Agnes Ayton
Original Assignee
Laxdale Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9944164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20051847(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laxdale Ltd filed Critical Laxdale Ltd
Publication of NO20051847L publication Critical patent/NO20051847L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Eikosapentaensyre (EPA) anvendes i behandlingen av anoreksia nevrosa, bulimi og relaterte kliniske syndromer.
NO20051847A 2002-09-16 2005-04-15 Eikosapentaensyre (EPA) for behandling av anoreksia nevrosa (AN) og bulimi. NO20051847L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0221480.7A GB0221480D0 (en) 2002-09-16 2002-09-16 Treatment of anorexia nervosa (AN) and bulimia
PCT/GB2003/003985 WO2004024136A1 (en) 2002-09-16 2003-09-16 Eicosapentaenoic acid (epa) for treating anorexia nervosa (an) and bulimia

Publications (1)

Publication Number Publication Date
NO20051847L true NO20051847L (no) 2005-04-15

Family

ID=9944164

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051847A NO20051847L (no) 2002-09-16 2005-04-15 Eikosapentaensyre (EPA) for behandling av anoreksia nevrosa (AN) og bulimi.

Country Status (20)

Country Link
US (1) US20060135608A1 (no)
EP (1) EP1556028A1 (no)
JP (1) JP2006503031A (no)
KR (1) KR20050042823A (no)
CN (1) CN1694694A (no)
AU (1) AU2003269138A1 (no)
BR (1) BR0317857A (no)
CA (1) CA2499142A1 (no)
GB (1) GB0221480D0 (no)
HR (1) HRP20050245A2 (no)
IS (1) IS7744A (no)
MX (1) MXPA05002943A (no)
NO (1) NO20051847L (no)
NZ (1) NZ538793A (no)
PL (1) PL375726A1 (no)
RS (1) RS20050226A (no)
RU (1) RU2330653C2 (no)
TW (1) TW200410682A (no)
WO (1) WO2004024136A1 (no)
ZA (1) ZA200502161B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
WO2005046668A1 (ja) * 2003-11-14 2005-05-26 Mochida Pharmaceutical Co., Ltd. 言語障害予防・治療剤
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
WO2008081989A1 (ja) 2006-12-28 2008-07-10 Suntory Holdings Limited 神経再生剤
US8816110B2 (en) 2007-02-15 2014-08-26 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
DK2121576T3 (en) 2007-02-15 2016-02-15 Ct De Rech Sur Les Biotechnologies Marine Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
WO2008113177A1 (en) 2007-03-20 2008-09-25 Centre De Recherche Sur Les Biotechnologies Marines Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
US8455472B2 (en) * 2009-06-15 2013-06-04 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
KR20140007430A (ko) * 2011-02-11 2014-01-17 이 아이 듀폰 디 네모아 앤드 캄파니 에이코사펜타엔산 농축물
US9447020B2 (en) 2013-10-31 2016-09-20 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
RU2545988C1 (ru) * 2013-11-12 2015-04-10 Государственное бюджетное учреждение здравоохранения города Москвы Московский клинический научно-практический центр Департамента здравоохранения города Москвы Способ лечения хронического запора и функциональной анорексии
CN111971041A (zh) 2018-02-07 2020-11-20 Scf制药股份有限公司 多不饱和脂肪酸单甘油酯、组合物、方法及其用途
WO2019204218A1 (en) * 2018-04-16 2019-10-24 Quadrant Biosciences Inc. Salivary microrna levels in anorexia nervosa provide a liquid biopsy of metabolic and neuropsychiatric status
AU2019264159A1 (en) 2018-05-03 2020-12-24 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof
CN109276262B (zh) * 2018-07-30 2021-01-26 中国科学院心理研究所 一种用于筛选高危进食障碍的检测系统
US20210299065A1 (en) * 2020-03-27 2021-09-30 Homeostasis Therapeutics, Limited Methods of treatment for anorexia nervosa, bulimia and related clinical syndromes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077828A (en) * 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes

Also Published As

Publication number Publication date
RU2330653C2 (ru) 2008-08-10
JP2006503031A (ja) 2006-01-26
GB0221480D0 (en) 2002-10-23
WO2004024136A1 (en) 2004-03-25
ZA200502161B (en) 2005-09-15
RS20050226A (en) 2007-09-21
RU2005107416A (ru) 2006-01-20
CA2499142A1 (en) 2004-03-25
HRP20050245A2 (en) 2005-10-31
CN1694694A (zh) 2005-11-09
BR0317857A (pt) 2005-12-06
PL375726A1 (en) 2005-12-12
TW200410682A (en) 2004-07-01
EP1556028A1 (en) 2005-07-27
US20060135608A1 (en) 2006-06-22
AU2003269138A1 (en) 2004-04-30
NZ538793A (en) 2007-05-31
MXPA05002943A (es) 2005-06-03
IS7744A (is) 2005-03-15
KR20050042823A (ko) 2005-05-10

Similar Documents

Publication Publication Date Title
NO20051847L (no) Eikosapentaensyre (EPA) for behandling av anoreksia nevrosa (AN) og bulimi.
ATE423559T1 (de) Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren
RS93604A (en) Substituted phenylacetamides and their use as glucokinase activators
AU2003295912A1 (en) Electro-osmotic pumps and micro-channels
DK1206474T3 (da) Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
TR200200160T2 (tr) Antiinflamatuar ajanlar olarak imidazoller ve triazoller
DE60111570D1 (de) Isoindolin-1-on als glukokinaseaktivatoren
BR0312785A (pt) Tratamento de desordens relacionadas a tnf(alfa)
SE0102315D0 (sv) Compounds
RS20060320A (en) Substituted indazole-o-glucosides
NO20055741D0 (no) Nye kjemiske forbindelser
SG130189A1 (en) Substituted indole-o-glucosides
NO20071378L (no) Tiazolo-naftylsyrer.
IS7858A (is) Samsetning til notkunar í meðferð á athyglisbresti með ofvirkni (ADHD)
NO20024240L (no) Nye arylfruktose-1,6-bisfosfataseinhibitorer
ATE312096T1 (de) Neue verbindungen
BR0315644A (pt) Piperazinil e diazapanil benzamidas e benzotioamidas
DK1648484T3 (da) Fremgangsmåde til behandling af arthritis-tilstande
NO20010860L (no) Nye forbindelser
GB2399019B (en) The structure containing the conductive medium for the source of the external high-power focusing ultrasonic treatment
PT1419163E (pt) Imidazopiridinas triciclicas
DE60305522D1 (de) Pharmazeutische zusammensetzung enthaltend tenatoprazol und einen entzündungshemmer
ATE417856T1 (de) Motilidverbindungen
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer
EA200200853A1 (ru) Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application